Cardinal Health Inc. (NYSE:CAH) has seen a notable transaction from one of its top executives. Michelle D. Greene, the company's Chief Information Officer, sold 4,000 shares of Cardinal Health stock on August 19, 2024, at an average price of $108.85, resulting in a total sale value of over $435,000.
The transaction was part of a series of trades that included both acquisitions and disposals of shares by the executive. Prior to the sale, Greene had shares withheld to satisfy tax withholding obligations due to the vesting of restricted and performance share units on two separate occasions. On August 15, shares valued at approximately $250,477 were withheld at a price of $106.36 per share, and on August 16, an additional $161,109 worth of shares were withheld at a price of $107.91 per share.
Additionally, Greene was granted restricted stock units (RSUs) that will vest in three equal annual installments starting from August 15, 2025. The grant, which occurred on August 15, involved 4,819 RSUs at a transaction price of $0.0, indicating these shares were awarded to the executive as part of her compensation package and did not involve a market purchase.
Following these transactions, Greene's ownership in the company stands at 19,242 common shares. The sales were conducted in multiple transactions at prices ranging from $108.67 to $108.97, with the executive committing to provide full information on the number of shares sold at each price upon request.
Investors often monitor insider transactions like these for insights into executives' perspectives on the company's stock value and future performance. However, such transactions can be influenced by a variety of factors and do not necessarily indicate a direct correlation with the company's operational success or challenges.
Cardinal Health, headquartered in Dublin, Ohio, is a global, integrated healthcare services and products company known for its distribution of pharmaceuticals and medical products.
In other recent news, Cardinal Health reported a 29% increase in earnings per share (EPS) for its fourth quarter and fiscal year 2024, alongside a 12% rise in fourth-quarter revenue to $59.9 billion. The fiscal year 2024 revenue also climbed by 11% to $227 billion, with the pharmaceutical and specialty solutions segment significantly contributing to this growth. The company revised its fiscal year 2025 guidance upwards, projecting an EPS between $7.55 and $7.70. Deutsche Bank (ETR:DBKGn), TD Cowen, and Mizuho have all increased their price targets for Cardinal Health, reflecting confidence in the company's financial performance and growth prospects.
The company's pharmaceutical and specialty solutions segment is expected to decline by 4-6% due to the expiration of the OptumRx contract. However, Cardinal Health is optimistic about the prospects of its Global Medical Products Distribution segment, which ended the year with a profit of $205 million, a $240 million improvement year over year. This segment is on track to meet its $300 million profit target by fiscal year 2026.
Cardinal Health is also investing in its Nuclear and Precision Health Solutions business and plans to further develop atHome solutions and OptiFreight to drive long-term growth. Despite expected challenges such as insulin pricing changes and slow biosimilar market penetration, the company is confident in its strategic progress and ability to capitalize on growth opportunities. Key partnerships, like the Averon joint venture with CVS Health (NYSE:CVS), are expected to drive future growth.
InvestingPro Insights
Cardinal Health Inc. (NYSE:CAH) has been in the spotlight with insider trading activity, but investors looking for a broader perspective on the company's financial health and performance can turn to InvestingPro for a deeper analysis. According to InvestingPro data, Cardinal Health boasts a market capitalization of $26.78 billion and a P/E ratio of 31.49, which reflects investors' valuation of the company relative to its earnings.
However, when looking at the adjusted P/E ratio for the last twelve months as of Q4 2024, the figure is more attractive at 16.77. This suggests that when accounting for certain adjustments, the stock may be more reasonably priced relative to its earnings. Additionally, the company's PEG ratio during the same period stands at 0.18, indicating potential undervaluation when considering its earnings growth rate.
InvestingPro Tips for Cardinal Health highlight several key factors that could influence investor decisions. The management's aggressive share buyback strategy and the company's impressive track record of raising its dividend for 36 consecutive years, now standing at 42 years according to the latest data, signal confidence in its financial stability and commitment to returning value to shareholders. Moreover, analysts expect net income growth this year, which could be a positive sign for future performance. For those seeking more comprehensive insights, there are additional tips available on InvestingPro, including analysis on earnings revisions, stock volatility, and valuation multiples.
For investors interested in a deeper dive into Cardinal Health's performance metrics and strategic initiatives, more InvestingPro Tips can be found at https://www.investing.com/pro/CAH. These tips offer valuable guidance on the company's position within the Healthcare Providers & Services industry and its financial health, which could be particularly relevant in light of recent insider transactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.